Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Glucocorticoid Use in Rheumatoid Arthritis Management Focus of Ongoing Debate

Gretchen Henkel  |  Issue: March 2015  |  March 1, 2015

 

If given in lower dosages, especially with attention to the body’s circadian cycles, glucocorticoids function as hormone replacement for adrenal insufficiency. ‘You don’t expect any damage because you give the right dosage at the right time; it’s like giving insulin in diabetes.’

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

 

—Dr. Cutolo

Dr. Pincus says he has not treated patients for more than a week with more than 10 mg or more than a month with more than 5 mg in 25 years. He reports no increase in hypertension, diabetes or cataracts in RA patients treated with prednisone over long periods, including more than 100 patients treated over more than eight years. No significant differences were seen in efficacy in patients treated with <5 vs. 5 or more mg/day.6 He also reports substantially better status after 2000, compared to the 1980s, according to joint counts, radiographs, laboratory tests and patient questionnaire responses in patients who took never took more than 5 mg.7

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Boers is careful to counsel his patients regarding possible side effects from taking glucocorticoids. For example, he advises them to resist the feelings of abnormal hunger, which may accompany the first few weeks of therapy, and to eat normal amounts to avoid weight gain. Before an injection of the drugs, he warns them about the effects of restlessness and a boost of energy. “If you explain things, people are very accepting,” he says.

Timing Is All

Dr. Cutolo has conducted many studies on the use of nighttime-release prednisone to combat the morning stiffness that is characteristic in RA, and which is a consequence of the circadian night reactivation of the immune/inflammatory process. If given in lower dosages, especially with attention to the body’s circadian cycles, says Dr. Cutolo, glucocorticoids function as hormone replacement for adrenal insufficiency. “You don’t expect any damage because you give the right dosage at the right time; it’s like giving insulin in diabetes,” he says.

Dr. Cutolo
Dr. Cutolo

The theory behind this approach is that the clinical efficacy of late-night (as opposed to upon-awakening) prednisone should prevent patients’ symptoms of morning stiffness. In fact, as already seen in such physiological conditions as polymyalgia rheumatica, the gradual rise of cortisol in the very early morning hours downregulates ongoing immune reactivity. The stiffness and resulting functional disability that RA patients experience upon awakening is consistent, he says, with the reduced physiological adrenal cortisol production during the night in realized chronic inflammatory conditions, which becomes insufficient to inhibit the ongoing immune/inflammatory reaction.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:ArthritisdebateglucocorticoidHenkelrheumatologistSteroidtherapy

Related Articles

    The Peripatetitc Theodore Pincus, MD

    July 1, 2007

    Tireless champion for patient self-report

    Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?

    April 1, 2013

     Long-term, low-dose prednisone at less than 5 mg/day appears tolerable and effective for many patients with rheumatoid arthritis (RA)

    The Science of MDHAQ/RAPID3 Scores

    December 12, 2011

    Do patient self-reports provide valid data for evidence-based care in rheumatology practice?

    Chronotherapy with Glucorticoids in Rheumatoid Arthritis

    January 17, 2011

    Time is of the essence in balancing risks and benefits

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences